(Q34154708)

English

Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

(-)-homoharringtonine

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Liu-Fang Gu

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Wang-Gang Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Fang-Xia Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Xing-Mei Cao

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Yin-Xia Chen

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Ai-Li He

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jie Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Xiao-Rong Ma

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

9 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

137

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

997-1003

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Inhibition of Translation in Eukaryotic Systems by Harringtonine

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

1st International Conference on Reversal of Multidrug Resistance in Cancer. St. Gallen, Switzerland, 1-3 September 1994.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of [...]

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0947-Z

21 January 2018

Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Harringtonine, an inhibitor of initiation of protein biosynthesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Effect of several anti-tumor drugs on apoptosis induction in Jurkat cell line]

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The genus Cephalotaxus: source of homoharringtonine and related anticancer alkaloids

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical investigation of homoharringtonine

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined harringtonine or homoharringtonine chemotherapy for acute nonlymphocytic leukemia in 25 children

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21152934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-010-0947-Z

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

release_w3mwcbnrabh7botbjhk4q6x6te

1 reference

https://api.fatcat.wiki/v0/release/w3mwcbnrabh7botbjhk4q6x6te

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34154708&oldid=2196320759"